文献速递前列腺癌

RAPID MRI引导前列腺癌诊断路径中MRI阴性或活检阴性男性的5年结局

Five-year Outcomes for Men after Negative Magnetic Resonance Imaging (MRI) or Negative Biopsy in the RAPID MRI-directed Prostate Cancer Diagnostic Pathway.
PubMed 文献 · Eur Urol · 2025-11-07

这项单中心队列研究随访了RAPID路径中MRI阴性未活检或活检阴性的1266名男性,中位随访3.4年。5年GG≥2无诊断生存率为91.9%,无治疗生存率为94.4%,无转移或癌因死亡,四成男性避免活检。

要点

  • 5年GG≥2无诊断生存率91.9%,无治疗生存率94.4%
  • 无转移或癌症相关死亡发生
  • 未活检组5年无活检生存率79.6%,原队列39%避免活检

核心结论

  • RAPID MRI引导路径对男性活检分诊安全,5年仅1/13出现GG≥2癌症、1/20需治疗,四成避免活检。

研究设计与样本

  • 单中心队列研究,2017至2023年RAPID路径出组男性,随访至少3个月,共评估1266例(927例未活检,339例活检阴性)。
  • 中位随访3.4年(四分位距2.4-4.9年)。

主要发现

  • 5年GG≥2无诊断生存率91.9%(95%CI 90.0-93.9%),GG≥3为96.3%(95%CI 95.0-97.7%),GG 1为99.4%(95%CI 98.9-99.8%)。
  • 5年无治疗生存率94.4%(95%CI 92.6-95.9%)。
  • 未活检组5年无活检生存率79.6%(95%CI 73.7-85.8%),原队列39%(899/2334)避免活检。
  • 无转移或癌症相关死亡;PSAD、PI-RADS评分及活检阴性(含ASAP或HGPIN)未预测GG≥2诊断和治疗。

关键数值与推荐

  • MRI PI-RADS/Likert 1-2分或3分且PSAD<0.12 ng/ml2者行PSA监测;3分且PSAD>0.12 ng/ml2或4-5分者建议前列腺活检。

临床怎么用

  • RAPID路径可用于安全分诊男性是否需活检,MRI阴性或活检阴性者可随访监测,避免不必要活检。

局限性

  • 19%数据因随访时间短被排除,且为单中心评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: There is uncertainty over medium-term cancer outcomes for men who avoid biopsy (Bx) after nonsuspicious magnetic resonance imaging (MRI), and men with a negative Bx after suspicious MRI findings. We report on cancer diagnosis, treatment, and Bx rates for this population over a period of 5 yr. METHODS: This single-centre cohort study followed men discharged from the RAPID prostate cancer diagnostic pathway between 2017 and 2023 with either negative MRI or negative prostate Bx, with at least 3 mo of follow-up. Patients with a Prostate Imaging-Reporting and Data System (PI-RADS) or Likert score of 1-2 on MRI or a score of 3 and prostate-specific antigen (PSA) density (PSAD) of <0.12 ng/ml2 underwent PSA monitoring, while those with a score of 3 and PSAD >0.12 ng/ml2 or a score of 4-5 were offered prostate Bx. Primary outcomes were grade group (GG) ≥2 diagnosis-free survival (Dx-FS) and treatment-free survival (TFS). Secondary outcomes were GG ≥3 Dx-FS, GG 1 Dx-FS, Bx-free survival (Bx-FS), cancer-specific survival, metastasis, and re-referral. Data were collected using a prospective data registry and electronic clinical records; patients with no recent follow-up (>1 yr) were directly contacted. Kaplan-Meier plots and multivariable Cox regression were used for statistical analysis. KEY FINDINGS AND LIMITATIONS: Of 2334 men investigated within the RAPID pathway, 1266 (927 no Bx, 339 negative Bx) were evaluated. Median follow-up was 3.4 yr (interquartile range 2.4-4.9). Seventy-four had GG ≥2 cancer and seven had GG 1 cancer. The 5-yr Dx-FS rates were 91.9% (95% confidence interval [CI] 90.0-93.9%) GG ≥2, 96.3% (95% CI 95.0-97.7%) for GG ≥3, and 99.4% (95% CI 98.9-99.8%) for GG 1. The 5-yr TFS rate was 94.4% (95% CI 92.6-95.9%). The 5-yr Bx-FS rate in the no-Bx group was 79.6% (95% CI 73.7-85.8%), leaving 39% (899/2334) of the original cohort Bx-free. No metastases or cancer-related deaths occurred. Higher PSAD and PI-RADS score and negative Bx, including atypical small acinar proliferation and high-grade prostatic intraepithelial neoplasm findings, did not predict GG ≥2 diagnosis and treatment. Limitations include data excluded because of short follow-up (19%) and the single-centre evaluation. CONCLUSIONS AND CLINICAL IMPLICATIONS: The RAPID MRI-directed pathway is safe in triaging men for Bx. At 5 yr, only one in 13 patients discharged from the RAPID pathway had GG ≥2 cancer and one in 20 required cancer treatment, while four in ten avoided Bx.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Ng CPY, Light A, Eragamreddy SK, et al. Five-year Outcomes for Men after Negative Magnetic Resonance Imaging (MRI) or Negative Biopsy in the RAPID MRI-directed Prostate Cancer Diagnostic Pathway. Eur Urol. 2025. PMID: 41206290. doi:10.1016/j.eururo.2025.10.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。